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Ovine enzootic abortion, caused by Chlamydia abortus, leads to important economic 
losses worldwide. In addition to reproductive failures, infection may impact lamb growth 
during the first weeks after birth, yet this effect has not been well characterized. Vaccination 
can help to control the disease but variable efficacy values have been described, pos-
sibly related with factors associated with the host, the vaccine, the parameter used 
for efficacy determination, and the challenge conditions. In this context, we evaluated 
the efficacy of an inactivated standard commercial vaccine and a 1/2 diluted dose in 
pregnant sheep challenged with C. abortus by examining multiple indicators of vaccine 
effect (including incidence of reproductive failures, bacterial excretion, and evolution of 
weight gain of viable lambs during the first month of life). Three groups of ewes [control 
non-vaccinated, C (n = 18); vaccinated with standard dose, SV (n = 16); and vaccinated 
with 1/2 dose, DV (n = 17)], were challenged approximately 90 days post-mating and 
tested using direct PCR (tissue samples and vaginal swabs) and ELISA (serum) until 
31 days post-reproductive outcome. There were not significant differences in the pro-
portions of reproductive failures or bacterial shedding after birth/abortion regardless the 
vaccination protocol. However, a beneficial effect of vaccination on offspring growth was 
detected in both vaccinated groups compared with the controls, with a mean increase in 
weight measured at 30 days of life of 1.5 and 2.5 kg (p = 0.056) and an increase in the 
geometric mean of the daily gain of 8.4 and 9.7% in lambs born from DV and SV ewes 
compared with controls, respectively. Our results demonstrate the effect of an inactivated 
vaccine in the development of the offspring of C. abortus-infected ewes at a standard 
and a diluted dose, an interesting finding given the difficulty in achieving sufficient antigen 
concentration in the production of enzootic abortion of ewes-commercial vaccines.
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inTrODUcTiOn
Chlamydia abortus is an obligate intracellular, Gram-negative 
bacterium that belongs to the family Chlamydiaceae (1). 
Ruminants are its main hosts, and infection leads to a disease, 
known as enzootic abortion of small ruminants, characterized 
by reproductive failures (late-term abortion, neonatal death, and 
premature offspring). In addition, C. abortus infection can be 
responsible for weak/low birth-weight lambs (2, 3) and can affect 
early lamb development (4), although the contribution of this key 
aspect on the full impact caused by the disease has not been char-
acterized in detail. The disease has a worldwide distribution and 
is recognized as a major cause of economic loss in most sheep-
rearing regions [including Northern Europe, North America, and 
Africa (5)], with the exception of Australia and New Zealand (6), 
and is considered the main cause of infectious abortion in sheep 
[enzootic abortion of ewes (EAE)] in the United Kingdom (7) and 
Switzerland (8). In addition, C. abortus may be a zoonotic agent 
that can induce reproductive disorders in pregnant women (5).
In EAE-infected flocks, ewes shed high amounts of C. abortus 
in vaginal discharges during abortion/parturition and thus pla-
centa, fetuses, and lamb coats born to infected ewes are heavily 
contaminated. Susceptible animals can become easily infected by 
the ingestion of contaminated material (9) or the inhalation of 
aerosols (10). EAE-affected ewes will develop an effective post-
infection immune response preventing future C. abortus-induced 
abortions (11), but may still shed the bacteria in the following 
estrus, contributing to the maintenance of the infection in the 
flock. The reproductive failure rate in a newly infected naive 
sheep flock is around 30% (up to 60% in goat herds), whereas in 
endemically infected flocks, prevalence is around 10% (12). The 
most effective strategy for prevention of EAE is the immuniza-
tion of susceptible individuals (9). Vaccination strategies aim to 
trigger a protective immune response similar to that occurring 
after abortion in EAE-infected ewes (13). Nowadays, currently 
available vaccines against C. abortus include inactivated and live-
attenuated products (14). The live temperature-sensitive attenu-
ated vaccine has been shown to offer good protection against 
C. abortus-induced abortion in field trials (9, 15). However, 
given the zoonotic nature of the microorganism, and the recent 
description of outbreaks of abortions in vaccinated flocks in 
which a vaccine strain was implicated (16, 17), this commercially 
available attenuated vaccine pose safety concerns. By contrast, 
inactivated vaccines, prepared from egg-grown strains or cell 
cultures, have been widely used in the control of EAE since its 
infection nature was discovered in the 1950s, and its efficacy has 
been well documented (4, 18–21), leading to its recommendation 
as a useful control option by the OIE (14). However, although 
inactivated vaccines may reduce the abortion rate, they do not 
completely prevent bacterial shedding and reproductive failures 
may still occur (9). In addition, the efficacy of inactivated vaccines 
is highly variable (9), with reports of occasional EAE outbreaks in 
vaccinated flocks (22–24).
Vaccine efficacy trials are usually focused on assessing the 
impact of vaccination on the abortion rate and bacterial excre-
tion, as well as parameters related to viable lambs at birth [lamb 
weight and kilograms of lamb per ewe (4)]. However, as discussed 
earlier, the effect of vaccination in the early development of viable 
offspring has not been thoroughly studied, despite being a key 
aspect contributing to the full economic impact of EAE.
In this context, the aim of the present study was to assess the 
efficacy of a full and a diluted dose of a commercial inactivated 
vaccine against EAE on eliciting a protective immune response 
against a subsequent C. abortus challenge in pregnant sheep, 
considering not only classical microbiological and clinical 
parameters but also for the first time a detailed evaluation of the 
weight development of the offspring.
MaTerials anD MeThODs
animals and experimental Design
A total of 80 primiparous 10-month age crossbreed “Merino” ewes 
were randomly selected from a flock without history of abortions 
located in Central Spain. This sample size was selected in order to 
achieve at least 20 pregnant sheep in each of the vaccinated groups 
of study (as required by the European Pharmacopoeia for ovine 
vaccines against other infectious abortifacient diseases) (25). All 
animals tested negative for C. abortus, Salmonella enterica serovar 
Abortusovis, Brucella spp., Toxoplasma gondii, Coxiella burnetii, 
and Maedi-Visna virus before being included in the study. Sheep 
were then randomly allocated in three experimental groups: 
SV (standard vaccine, n =  25), DV (diluted vaccine, n =  29), 
and C (control group, n = 26). Finally, the number of pregnant 
sheep that we obtain was 16 in SV group, 17 in DV, and 18 in 
group C. Food and water were provided ad libitum throughout 
the study. All husbandry practices and animal procedures were 
authorized by the scientific and animal experiments committee 
of Complutense University of Madrid (98/2012) and the Animal 
Research Committee from the Madrid Region (10/176335.9/11).
Vaccination Protocol
Animals from Group SV were vaccinated with a commercial 
bivalent vaccine against C. abortus (concentration of 107.8 egg 
lethal dose 50) and Salmonella enterica serovar Abortusovis 
(concentration of 2 × 109 colony-forming units) in oiled adjuvant. 
Sheep belonging to group DV were immunized with a 1/2 dilu-
tion of the commercial vaccine. Finally, ewes from group C were 
inoculated with 0.85% saline sterile solution (control group). In 
the three groups, the vaccination protocol consisted in a 2-ml first 
dose applied at day 0 and a booster of 2-ml applied 29 days later. 
Vaccines and saline solution were inoculated subcutaneously in 
the axillary region.
Breeding Protocol
Sixteen days after inoculation of the first dose [16  days post-
vaccination (d.p.v.)], ewes were mated with C. abortus seronega-
tive rams. Previously, estrus of the sheep had been synchronized 
using vaginal sponges with cronolone (Chronogest®, MSD, 
Salamanca, Spain) and a intramuscular injection of mare serum 
gonadotroping (Folligon®, MSD, Salamanca, Spain), according 
to the manufacturer’s instructions. Pregnancy was confirmed by 
transabdominal ultrasound at 60  d.p.v. All pregnant sheep (16 
ewes in group SV, 17 ewes in group DV, and 18 ewes in group C) 
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were placed in different barns depending on the experimental 
group.
experimental challenge
After 103 d.p.v. (87 days after breeding), all animals were chal-
lenged using 2  ml of a 5 ×  106  inclusion-forming units/ml of 
C. abortus (dose per animal: 1 ×  107 inclusion-forming units) 
inoculated subcutaneously. The challenge inoculum was prepared 
from a culture of the pathogenic C. abortus AB7 strain grown in 
yolk sacs of developing chicken embryos. Titers of inocula were 
established by culture in MCoy cell line and subsequent count 
of inclusion-forming units, as previously described by Buendía 
et al. (26). The original inoculum was stored at −80°C until the 
challenge, when it was reconstituted in sterile phosphate-buffered 
saline (PBS) solution.
sampling strategy
Serum samples were collected at 0 and 29 d.p.v., biweekly until 
the beginning of the abortions/parturitions and weekly since 
then to the end of the study. Rectal temperature between days 0 
and 6 post-challenge was measured daily. Vaginal swabs from all 
ewes were collected within the first 3 days post-parturition/abor-
tion and then weekly for at least 21 days after the reproductive 
outcome using commercial sterile swabs with transport media 
for Chlamydia (Deltalab, Barcelona). Samples from spleen, liver, 
lung, and stomach content (as well as cotyledons, when available) 
from all aborted/non-viable lambs were collected immediately 
after delivery. Vaginal swabs and tissue samples were processed 
immediately after collection or stored at −80°C.
laboratory Tests
PCR Detection of C. abortus
Vaginal swabs were resuspended on 1.5  ml of sterile PBS and 
subjected to DNA extraction using QIAamp MinElute Virus Spin 
Kit (Qiagen, Las Rozas, Madrid) according to the manufacturer’s 
instructions. Tissue samples from fetuses and dead lambs were 
processed using the DNEasy Blood and Tissue Kit (Qiagen, Las 
Rozas, Madrid), according to the manufacturer’s instructions. 
DNA extracted from all samples was analyzed using a real-time 
PCR, as previously described (27).
Serology
Serum was recovered from blood samples and analyzed using an 
ELISA commercial kit [ID Screen Chlamydophila abortus indirect 
multispecies (IDvet, Grabels, France)] according to the manufac-
turer’s instructions. This test expresses the result of a sample as 
the percentage of the optical density (%OD) value obtained in 
the positive controls adjusted by background readings as follows:
 
%OD
OD OD
OD OD
sample negative control
positive control negati
=
−
− ve control
×100
 
Samples with %OD values >60% were classified as positive.
statistical analysis
Vaccine effect was evaluated by comparing the values of the fol-
lowing indicators in the different study groups:
 1. Post-vaccination and post-challenge serological responses: 
ELISA results in the different sampling points after the 
vaccination/challenge were compared using the chi-square 
and Z-test for comparison of proportions of reactors and 
the Mann–Whitney and Kruskal–Wallis test with p-values 
adjusted using the Bonferroni method. Qualitative and quan-
titative ELISA responses were also compared depending on 
the reproductive outcome (reproductive failure with positive 
Chlamydia PCR result/negative PCR deliveries).
 2. Daily rectal temperature between days 0 and 6 post-challenge 
(d.p.c.): changes in the rectal temperatures before (0 d.p.c.) 
and after challenge (1–6  d.p.c.) were compared using 
Wilcoxon test.
 3. Number of reproductive failures (abortion/stillbirth lambs/
weak lambs that died in the first 5 days of life) associated with 
C. abortus infection (those in which DNA from the pathogen 
was detected by real-time PCR in offspring tissues, placenta, 
and/or vaginal swab from the mother). The relative risk of 
reproductive failure associated with C. abortus infection 
in each vaccinated group compared with the controls was 
calculated using the MedCalc Statistical Sofware bvba 15.8 
(Microsoft Partner, Ostend, Belgium) (28).
 4. Percentage of shedder animals, defined as those from sam-
ples in which C. abortus was positive (organs from fetuses/
non-viable offspring and/or vaginal swabs): proportions of 
positive ewes were compared using the Z-test for comparison 
of multiple proportions adjusted by the Bonferroni method.
 5. Total weight of lambs born per ewe: the mean total weight 
of lambs born from ewes in each group recorded at birth 
and at 30 days of life as well as the total gain achieved during 
those 30 days were compared using a mixed model including 
mother as a random effect and twins as a fixed effect.
 6. Daily weight gain of lambs from ewes of each group during 
the first 31 days of life (offspring development): to evaluate 
the effect of vaccination on the daily weight gain in the lambs 
from animals receiving the standard (SV group) and diluted 
(DV group) doses compared with the controls, a multivariable 
Bayesian regression model was fit, such that:
 y Ni,j i,j~ ( , )µ σ  
where yi,j represents the log-transformed weight from lamb i 
recorded in day j during the first 31 days after birth, and
 µ α β β β βi,j i i1 k ik= + + + +…0 1 2 2X X Xi  
with Xik denoting the kth covariate in lamb i with the correspond-
ing regression parameter βk and αi representing the random effect 
corresponding to lamb i (included to account for the lack of inde-
pendence between observations recorded from the same animal). 
The effect of the number of days after lambing (1–30), group of 
study of the mother (SV, DV, and C), type of pregnancy (single or 
twin) and the weight registered the day of birth were evaluated as 
fixed effects in the model. Non-informative Gaussian functions 
with mean 0 and variance 1,000 were used as prior distributions 
for the regression coefficients β0 and βk, and αi was assumed to fol-
low a normal distribution N(μα, σα), where μα  followed a  normal 
FigUre 1 | Percentage of optical density (%OD) in the elisa test per 
group (mean ± 95% confidence interval) between 0 and 182 days 
post-vaccination. Red line: group C (non-vaccinated control group). Blue 
line: Group SV (standard dose vaccine). Green line: group DV (1/2 dose 
vaccine). The horizontal continuous line indicates the cut-off of the ELISA test 
(60%OD). I: day of administration the first vaccine dose subcutaneously. II: 
day of administration the second vaccine dose subcutaneously. III: day of 
experimental infection with a dose of 1 × 107 inclusion-forming units of C. 
abortus strain AB7, applied subcutaneously. IV: beginning of reproductive 
events. Error bars: 95% confidence interval.
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distribution as described before and σα followed a uniform 
distribution (0.01, 100).
All tests for indicators 1–5 were performed using the software 
SPSS 20 (IBM, New York, NY, USA) (29) except when stated oth-
erwise, and interpreted considering a p-value of 0.05 to determine 
statistical significance. The normality of the quantitative values 
was assessed using the Kolmogorov–Smirnov test before further 
analyses were carried out.
Models for indicator 6 were run in WinBUGS 1.4 using the 
package R2WinBUGS from the software R 3. 0. 3 (30). Each 
model was evaluated using three Monte Carlo Markov Chains 
(MCMC) and convergence and mixing was assessed visually 
and more formally using the Gelman–Rubin Rˆ statistic (31, 32). 
Models were run for 5,000 iterations after discarding the first 
2,500 burn-in samples for obtaining the posterior estimates, 
and autocorrelation was eliminated by thinning the samples by 
collecting one in 10 consecutive samples. The best model was 
selected by exploring the combination of variables and two-way 
interactions that best explained the observed data based in 
Deviance Information Criterion (DIC) (33). Model checking was 
performed by comparing the observed data with the posterior 
predictive distribution of the observations generated using the 
fitted model, as previously described (34).
resUlTs
Post-Vaccination and Post-challenge 
serological responses
The day of vaccination all animals were seronegative in the ELISA 
test. Ewes from the control group (non-vaccinated) remained 
negative until the challenge, while positive responses were 
already recorded at 29 d.p.v. (first sampling post-vaccination) in 
both SV and DV groups (Figure 1). Most of the animals sero-
converted on day 29 (8/16 in the SV and 7/17 in the DV group), 
which was also the day when the largest proportion of reactors 
and higher %OD values before the challenge for group DV were 
recorded (41%, 7/17). By contrast, in the SV group, the overall 
maximum number of seropositive animals and %OD values were 
observed 2 weeks later (41 d.p.v., 56%, 9/16) (Figure 2; Table S1 in 
Supplementary Material). The proportion of reactors decreased 
37% (6/16) and 29% (5/17) in SV and DV groups, respectively, 
prior to the challenge (performed at day 103 d.p.v.) (Figure 2; 
Table S1 in Supplementary Material). Seven and four animals in 
the DV and SV groups did not seroconvert prior to the challenge 
(Table S1 in Supplementary Material), respectively. Proportion 
of positive reactors and %OD between vaccination and challenge 
were higher in the SV group than in the DV and the controls 
(Figures 1 and 2; Table S1 in Supplementary Material), although 
no significant differences in any sampling day were observed 
between vaccinated groups (p > 0.05).
After the challenge and before the beginning of reproduc-
tive outcomes, the highest proportion of reactors in the three 
groups was observed at 14 d.p.c. (117 d.p.v.), ranging from 7/17 
in DV group (significantly lower than in the C group, p < 0.05) 
to 10/16 and 15/18 in the SV and C groups (Figure 2, Table S1 
in Supplementary Material). No significant differences in the 
proportion of reactors were detected in subsequent samplings. 
Animals from group C showed the highest %OD values (Figure 1), 
although differences were only significant 14  d.p.c. (117 d.p.v) 
(Kruskal–Wallis test, p =  0.03), when differences between the 
C and DV groups were detected (Pairwise-comparison with 
Bonferroni adjustment, p = 0.024). The four ewes from the SV 
and four out of the seven ewes in the DV that did not seroconvert 
after vaccination were also never positive after the challenge. 
From the group of ewes that were positive at some stage after 
the vaccination, 16 were positive in the first sampling after the 
challenge, and only 4 became positive at some point afterward 
(Table S1 in Supplementary Material).
Finally, the increase in the %OD after the reproductive 
outcomes was observed regardless the study group, with no 
significant differences in the qualitative or quantitative ELISA 
results between groups detected in any sampling day (Figures 1 
and 2; Table S1 in Supplementary Material). However, if ELISA 
results were sorted in relation to the reproductive outcome (days 
post-reproductive outcome, d.p.r.) significantly higher %OD 
values were observed for samples collected within 1 week before 
and within 1, 2, and 3 weeks after the reproductive outcome in 
animals with a positive PCR result (Figure  3). Percentage of 
reactors was also significantly higher (p < 0.05) for PCR-positive 
animals for samples collected within 15–21 (10/13 vs. 14/37) 
d.p.r. (Figure 4). No differences in the ELISA results depending 
FigUre 2 | Percentage of elisa positive animals between 0 and 182 days post-vaccination. Red bars: group C (non-vaccinated control group). Blue bars: 
Group SV (standard dose vaccine). Green bars: group DV (1/2 dose vaccine). Error bars indicate SEs. I: day of administration the first vaccine dose subcutaneously. 
II: day of administration the second vaccine dose subcutaneously. III: day of experimental infection with a dose of 1 × 107 inclusion-forming units of C. abortus strain 
AB7, applied subcutaneously. IV: beginning of reproductive events.
FigUre 3 | Percentage of optical density (%OD) in the elisa test (mean ± 95% confidence interval) from 29 days prereproductive outcome to 
21 days after reproductive outcome, depending on the association of reproductive failure with C. abortus infection. Error bars: 95% confidence interval. 
Gray line: ewes with reproductive failure associated with C. abortus. Black line: ewes with reproductive outcome not associated with C. abortus infection.
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TaBle 1 | summary of reproductive events and C. abortus real-time Pcr results in tissues from fetuses/dead lambs and vaginal swabs from ewes after 
challenge observed in each experimental group.
no. ewes no. ewes with + Pcr of 
dead offspring and/or Vs 
at some point
Positive vaginal swab Pcr results
0–3  
DPr
4–14  
DPr
15–22  
DPr
23–30  
DPr
0–30 DPr  
(total group)
Group SV Abortion/stillbirth 1 1 1/1 0/1 1/1 0/1 1/1 (7/16)
Weak lambs 5 3 2/5 1/4 2/5 0/5 2/5
Healthy lambs 10 5 2/9 2/10 1/10 1/8 4/10
Group DV Abortion/stillbirth 3 3 2/3 2/3 1/3 1/2 2/3 (5/17)
Weak lambs 1 1 0/1 1/1 0/1 0/1 1/1
Healthy lambs 13 3 1/13 2/13 2/12 0/11 2/13
Group C Abortion/stillbirth 2 2 1/2 1/2 1/2 1/2 1/2 (4/17)
Weak lambs 1 1 0/1 0/1 0/1 0/1 0/1
Healthy lambs 14 3 3/13 2/14 2/14 0/11 3/14
Total (%) 50 22 12/48 (23%) 11/49 (22%) 10/49 (20%) 3/42 (7%) 16/50 (32%)
DPR, days post-reproductive outcome; Group SV, standard dose vaccine; Group DV, 1/2 dose vaccine; Group C, control ewes, non-vaccinated VS, vaginal swab. In the fraction, 
numerator indicates number of PCR-positive vaginal swabs and denominator indicates number of tested vaginal swabs.
FigUre 4 | evolution of percentage of positive animals in the elisa test from 29 days prereproductive outcome to 21 days after reproductive 
outcome, depending on the association of reproductive failure with C. abortus infection. Gray bars: ewes with reproductive failure associated with 
C. abortus. Black bars: ewes with reproductive outcome not associated with C. abortus infection. Error bars indicate SEs.
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on the study group for samples collected in any period before 
or after the reproductive outcome were observed.
Daily rectal Temperature
Comparison of temperatures measured on the day of the chal-
lenge and 1 d.p.c. revealed a mild though significant increase after 
the challenge for the DV (median increase of 0.3°C, p = 0.02) 
and C (median increase of 0.52°C, p = 0.006) groups while this 
was not observed for the SV group (median increase of 0.25°C, 
p =  0.1). No further significant increases of temperature were 
detected 2–6 d.p.c. compared with the temperature on the day of 
the challenge (data not shown).
reproductive Failures associated  
with C. abortus
One ewe from group C with a twin pregnancy died during 
delivery (lamb-tissues and vaginal swabs were PCR-negative) 
due to a dystocia and was excluded from analysis of proportions 
of reproductive failures. Results of the reproductive events and 
their PCR results per study group from the remaining animals are 
summarized in Table 1. A total of 4/17, 4/16, and 3/17 ewes from 
the SV, DV, and C groups, respectively, had a C. abortus-associated 
reproductive failure (Table 1). No significant differences in the 
relative risk of reproductive failure associated with C. abortus 
between the three groups or vaccinated vs. non-vaccinated groups 
TaBle 3 | Median parameters of the model measuring the association 
between the log-transformed weight recorded in 47 lambs during their 
first 30 days of life and the lamb-related variables.
Variable Value estimate 95% posterior  
probability interval
rhat
Intercept 1.010 0.978 1.043 1.0006
Vaccination group DV 0.080 0.052 0.109 1.0034
SV 0.093 0.064 0.121 1.0054
Type of pregnancy Twin −0.144 −0.120 −0.169 1.0004
Log of weight at birth 0.233 0.210 0.258 1.0022
SV, standard dose vaccine; DV, 1/2 dose vaccine.
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were observed (p > 0.05). While C. abortus DNA was detected in 
all abortions regardless the experimental group, it was only found 
in 3/5, 0/1, and 1/2 weak lambs born from mothers in groups SV, 
DV, and C, respectively. Three lambs born from ewes belonging 
to the SV, DV, and C groups (one lamb per ewe) died 17, 30, and 
6 days post-birth (with positive PCR results for lambs born from 
SV and DV ewes and negative results for the lamb born from the 
C ewe) but were not classified as weak for consistency with the 
pre-established definition.
Overall, a total of 13, 15, and 20 viable lambs were born from 
12 SV, 14 DV, and 15 C ewes, respectively. Twin gestations were 
observed in all experimental groups [n = 3 in group SV (one of 
these a parturition of three lambs), n = 2 in group DV and n = 6 
in group C].
Proportion of shedders per  
Vaccination group
No significant differences in the proportion of ewes shedding 
C. abortus (as determined by vaginal swabs and samples from 
dead offspring) depending on the study group or vaccination 
status (vaccinated vs. non-vaccinated) were detected (p > 0.05). 
Approximately 25% of the animals tested positive within the first 
3 d.p.r and in the following 22 days, and this proportion decreased 
in subsequent samplings up 7% approximately 4 weeks after the 
reproductive outcome (Table 1).
Total Weight of lambs Born per ewe
The mean total weight of lambs (15/17 in group SV, 14/16 in 
group DV, and 18/21 in group C) at 30 days of life was higher 
for the vaccinated groups compared with the control group 
(Table 2), but while lambs from the DV were slightly larger at 
birth those born from SV ewes were larger at 30  days of life 
(Table  2). The effect of the vaccination group of the ewe was, 
however, only borderline significant (p = 0.056) for the weight 
recorded at 30 days of life.
Daily Weight gain within the First  
31 Days of life
The weight gain in lambs born from ewes in groups SV and 
DV was greater than in lambs from group C, thus suggesting 
a relative but significant effect of vaccination on the weight of 
the offspring in the first 30 days of life (Table 3; Figure 5). An 
increase of the geometric mean of the non-transformed weight of 
9.7% (95% posterior probability interval 6.6–12.8) and 8.4% (95% 
posterior probability interval 5.4–11.5) was observed in lambs 
born from ewes receiving the standard (SV group) and diluted 
vaccination dose (DV group), while no differences between 
the weights recorded in lambs born from the two vaccinated 
groups were found. A large variation in the values estimated 
for the lamb-random effect that included the effect of the day 
of measurement was observed, highlighting the individual-level 
variability throughout the 30 days of measurements (Figure S1 in 
Supplementary Material).
Final models converged adequately as demonstrated by visual 
assessment of the MCMC, effective sample sizes, and the Rˆ value 
<1.1 found for all parameters, and predictive checking revealed 
an adequate fit of the model to the data.
DiscUssiOn
C. abortus, etiological agent of EAE, is one of the most impor-
tant pathogens for small ruminant production worldwide in 
terms of its economic impact. In the United Kingdom (the 
major sheep producer in Europe), alone the economic burden 
imposed by EAE was estimated to be around £20 million/
year (US$28 million) (35). Control of the disease is usually 
pursued using live or inactivated vaccines, but vaccine efficacy 
is variable and knowledge on the efficacy of currently avail-
able vaccine is limited. In the present study, the protection 
of a standard (group SV) and a 1/2 diluted dose (group DV) 
of a commercial vaccine against a C. abortus challenge was 
evaluated in pregnant sheep. Group DV was included in the 
study in order to evaluate vaccine efficacy at reduced doses, 
as previously described (36), since one of the major economic 
constraints in the production of EAE-commercial vaccines 
is the antigen concentration necessary to ensure an adequate 
protection (37). Although no differences in the incidence of 
abortions between the vaccinated and the control groups were 
observed, a protective effect of the vaccine on the lamb weight 
gain during the first month of life of the viable lambs was 
detected using a model that allowed the analysis of longitudinal 
data. This effect was observed regardless of the vaccine dose 
(standard or diluted) used.
Lack of differences between vaccinated and control groups 
had been reported also in previous studies using other commer-
cial inactivated vaccines (4, 12, 38, 39). However, the boost in the 
serological response detected by the ELISA in both vaccinated 
groups (Figure 1) highlights the immunogenicity of C. abortus-
inactivated vaccines, evident between 29 and 41 d.p.v., as previ-
ously reported (40–42) [showing group SV a higher response 
than group DV as observed in Wilsmore et  al. (3)], although 
TaBle 2 | Medium weight recorded at birth and 30 days of life and 
overall mean weight gain (in kilograms ± sD) measured in lambs born 
from ewes in the sV (standard dose vaccine), DV (1/2 dose vaccine), 
and c (control) groups.
Medium weight 
of lambs born per 
ewe at birth
Medium weight of 
lambs at 30 days 
post-partum
Medium weight 
gained in the 30 first 
days of life
Group SV 3.21 ± 1.10 9.28 ± 2.00 5.43 ± 1.53
Group DV 3.31 ± 0.79 8.21 ± 2.85 4.82 ± 2.29
Group C 2.90 ± 0.73 6.69 ± 2.30 3.87 ± 2.10
FigUre 5 | Daily weight recorded in 48 lambs born from ewes in the control (red dots), DV (1/2 dose vaccine, green dots), and sV (standard dose 
vaccine, blue dots) in the first 30 days of life.
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different inactivated vaccines have been also reported to induce a 
scarce (43) or null (4) serological response.
Experimental challenge induced a mild but significant 
increase in temperature 1 d.p.c. in the C and SV groups and a 
general seroconversion in all experimental groups, as previously 
described (Figure  1) (3, 4, 42, 44). A similar phenomenon 
(seroconversion) was observed in most animals after parturi-
tion/abortion in agreement with previous reports (Figure 1) (4, 
36, 44, 45). Significantly higher %OD values in animals with a 
reproductive failure associated with C. abortus compared with 
the rest of the ewes (Figure  3). This increase in the antibody 
levels when C.  abortus-associated reproductive failure occurs 
has been reported before (3, 36, 46, 47) and could be associated 
with the development of protective immunity against subsequent 
abortions (5).
Proportion of C. abortus-associated reproductive failures 
and ewes shedding C. abortus post-reproductive outcome (in 
vaginal swabs and/or their fetuses/dead lambs) were limited 
in all groups (<45 and <56%, respectively, Table  1) compared 
with previous studies that reported rates between 40 and 90% for 
reproductive failure (4, 48–52) and 40 and 100% for C. abortus 
shedding (4, 20, 42, 50). This finding could be explained at least 
in part by several factors. First, the moment of the experimental 
infection during the pregnancy has been demonstrated to impact 
the ability of the ewe to control it (11, 53, 54); here, the challenge 
was performed at approximately 85 ±  8  days of pregnancy in 
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contrast with previous reports in which it took place between 60 
and 75 days of pregnancy, considered the most susceptible period 
(2, 7, 42, 44, 46, 55). A challenge performed later during preg-
nancy could lead to a lower degree of colonization of the placenta 
and a milder infection and, ultimately, a lower level of excretion 
(thus being more difficult to detect by PCR) and a lower propor-
tion of abortions (9, 12) as supported by results based on a late 
(90–105 days post-mating) challenge (4, 23, 39). Second, samples 
from the placentas (the target tissue for C. abortus multiplica-
tion) (56) were only available from three ewes, what could have 
led to a more limited sensitivity of the direct PCR, a technique 
that has also been reported to be less sensitive than culture (57). 
Finally, lack of vaginal swabs collected at delivery/abortion for 
some animals that were sampled in days 1–3 post-reproductive 
outcomes may have contributed to the underdetection of animals 
with a limited and brief bacterial excretion after delivery.
Antibody responses are thought to play a role preventing 
C. abortus reinfection, although their protective effect against 
EAE is not fully understood (54). In fact, in the present study, 
10 ewes (8 vaccinated and 2 control) with different reproduc-
tive outcome (2 reproductive failures, 7 normal parturitions 
and the sheep from group C died during delivery, of which 
3 were positive in the PCR) never seroconverted during the 
study, demonstrating that serological responses do not always 
correlate with C. abortus previous contact, reproductive failure, 
or vaccine efficacy, in agreement with previous findings (11, 18, 
40, 44, 51, 56, 58). However, negative results in these animals 
(known to be exposed to C. abortus through vaccination and/
or challenge) could also be due to a lack of sensitivity of the 
ELISA used, based on the detection of antibodies against major 
outer membrane proteins (MOMPs), considered to be less sensi-
tive than tests based in polymorphic outer membrane proteins 
(POMPs) (9, 36, 44, 45).
As previously discussed, no significant impact of vaccination 
on the reproductive outcome was detected here. However, our 
results demonstrate that vaccination with the evaluated vaccine 
did have a beneficial effect on the weight gain of lambs born to 
vaccinated ewes (regardless the dose) during their first month of 
life. This effect, however, was not evident when overall weights 
recorded at 30  days of life or overall weight gain during those 
30  days were compared. The protective effect is in agreement 
with a previous study reporting an effect of vaccination on lamb 
weight during their first weeks of life (4). However, the ana-
lytical approach used here allowed us to account for other likely 
confounders (such as type of pregnancy or weight at birth) and 
quantified the effect on lamb weight.
In conclusion, the present study did not find a significant effect 
of immunization with an inactivated vaccine on prevention of 
reproductive failure at standard or diluted doses. However, a ben-
eficial effect of vaccination on lamb weight during the first month 
of life was found regardless the vaccination dose as evidenced by 
the association found between vaccination in the ewes and daily 
weight measured in the lambs, providing additional quantitative 
data that demonstrates the impact of C. abortus infection in a 
flock beyond the occurrence of reproductive failures. Further 
studies would be needed in order to determine the significance 
of our findings beyond the first month of age of the new-born 
lambs in terms of performance and health. In addition, our results 
highlight the usefulness of weight gain data for a full evaluation 
of vaccine efficacy.
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